CSIMarket
 

Zealand Pharma A  (NASDAQ: ZEAL)

Zealand Pharma A's

Competitiveness




 

ZEAL Sales vs. its Competitors Q4 2021







Revenue Growth Comparisons




Net Income Comparison


Zealand Pharma A recorded a net loss, as well as most of its competitors.

<<  ZEAL Stock Performance Comparisons



*Market share is calculated based on total revenue.





Publicly Traded Peers of Zealand Pharma A




Skye Bioscience Inc
Share Performance



+195.25%
30 Days



Skye Bioscience Inc
Profile

Skye Bioscience Inc operates under a business model focused on developing and commercializing innovative therapeutic treatments. The company primarily engages in research and development activities to discover novel drugs targeting specific medical conditions and diseases. Skye Bioscience Inc aims to generate revenue by successfully bringing these drugs to market through partnerships, licensing agreements, or direct sales.

More about Skye Bioscience Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 8.333 mill. $ - mill. $ -57.331 mill.

Sources: Zealand Pharma A’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Zealand Pharma A versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.